AVBP实时信号 | 通过Getagraph.com最大化利润

购买 136850 min ago

@ $21.16

发出时间: 15 Feb 2024 @ 04:35

回报率: -5.01%

上一信号: Feb 14 - 02:28

上一信号: 出售

回报率: -2.49 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	63 766.00
平均成交量	170 933
市值	673.23M
下一个收益日期	( $-0.580 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0870 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	555 555	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	313 076	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	3 616 041	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	4 761 903	Series B Preferred Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	55 000 000	Series A Preferred Stock

INSIDER POWER
-74.77
Last 24 transactions
Buy: 9 226 636 \| Sell: 63 909 387

音量相关性

長: 0.21 (neutral)

短: 0.97 (very strong)

Signal:(46.723) Expect same movement, but be aware

ArriVent BioPharma, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ArriVent BioPharma, Inc. 相关性 - 货币/商品

-0.23
( neutral )

0.03
( neutral )

-0.17
( neutral )

-0.11
( neutral )

-0.64
( weak negative )

0.24
( neutral )

Financial Reports:

No articles found.

ArriVent BioPharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.